Elevated Monocyte Count and Loss of Renal Function in Renal Transplant Patients.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 15 01 2020
revised: 15 02 2020
accepted: 23 02 2020
pubmed: 3 6 2020
medline: 16 2 2021
entrez: 3 6 2020
Statut: ppublish

Résumé

Rejection is an important factor affecting graft function in renal transplant patients. Development of acute rejection even after induction treatment suggests that humoral and cellular immune systems are not the only mechanisms responsible for this event. The innate immune system can play roles in rejection. The aim of this study is to evaluate the association between renal function and some absolute values and ratios of various hematologic parameters assessed before and after renal transplantation. This study included 63 renal transplant patients. Demographic features and laboratory findings were reviewed retrospectively and recorded. For cadaveric and spousal transplantations, induction treatment used antithymocyte globulin (ATG) (group 1 [G1]), and CD25 inhibitor was used for the others (group 2 [G2]). G2 was divided into 2 subgroups based on the estimated glomerular filtration rate (eGFR) decline rate: ≤ 3.5 mL/min/y as group 2a (G2a) and > 3.5 mL/min/y as group 2b (G2b). Hematologic parameters were compared across the groups. Compared to G1, G2 had higher mean blood pressure, blood urea nitrogen, creatinine, and first month post-transplant lymphocyte and monocyte counts (P = .034, P = .040, P = .003, P = .027, and P = .027, respectively). G2a had higher levels of first-month post-transplant white blood cell, monocyte, and neutrophil counts compared to G2b (P = .018, P = .038, and P = .011, respectively). Receiver operating characteristic analysis of the parameters in G2b showed that a monocyte count of > 750 mm Elevated monocyte count in patients who had faster eGFR decline and did not receive induction treatment with ATG points to the significance of the innate immune system.

Sections du résumé

BACKGROUND BACKGROUND
Rejection is an important factor affecting graft function in renal transplant patients. Development of acute rejection even after induction treatment suggests that humoral and cellular immune systems are not the only mechanisms responsible for this event. The innate immune system can play roles in rejection. The aim of this study is to evaluate the association between renal function and some absolute values and ratios of various hematologic parameters assessed before and after renal transplantation.
METHODS METHODS
This study included 63 renal transplant patients. Demographic features and laboratory findings were reviewed retrospectively and recorded. For cadaveric and spousal transplantations, induction treatment used antithymocyte globulin (ATG) (group 1 [G1]), and CD25 inhibitor was used for the others (group 2 [G2]). G2 was divided into 2 subgroups based on the estimated glomerular filtration rate (eGFR) decline rate: ≤ 3.5 mL/min/y as group 2a (G2a) and > 3.5 mL/min/y as group 2b (G2b). Hematologic parameters were compared across the groups.
RESULTS RESULTS
Compared to G1, G2 had higher mean blood pressure, blood urea nitrogen, creatinine, and first month post-transplant lymphocyte and monocyte counts (P = .034, P = .040, P = .003, P = .027, and P = .027, respectively). G2a had higher levels of first-month post-transplant white blood cell, monocyte, and neutrophil counts compared to G2b (P = .018, P = .038, and P = .011, respectively). Receiver operating characteristic analysis of the parameters in G2b showed that a monocyte count of > 750 mm
CONCLUSION CONCLUSIONS
Elevated monocyte count in patients who had faster eGFR decline and did not receive induction treatment with ATG points to the significance of the innate immune system.

Identifiants

pubmed: 32482450
pii: S0041-1345(20)30124-X
doi: 10.1016/j.transproceed.2020.02.176
pii:
doi:

Substances chimiques

Antilymphocyte Serum 0
Immunosuppressive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3080-3084

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Refika Buberci (R)

Department of Nephrology, Ankara Training and Research Hospital, Ankara, Turkey. Electronic address: refikakaraer@gmail.com.

Saime Paydas (S)

Department of Nephrology, Medical Faculty, Çukurova University, Adana, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH